Walleye Capital’s TG Therapeutics TGTX Stock Holding History

Walleye Capital’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$887K	Sell	26,700 -20,600	-44%	-$614K	﹤0.01%	2187
2025 Q4	$1.41M	Buy	47,300 +13,100	+38%	+$428K	﹤0.01%	2162
2025 Q3	$1.24M	Sell	34,200 -49,700	-59%	-$1.64M	﹤0.01%	1935
2025 Q2	$3.02M	Buy	83,900 +9,200	+12%	+$343K	0.01%	1203
2025 Q1	$2.95M	Buy	74,700 +23,200	+45%	+$781K	0.01%	1158
2024 Q4	$1.55M	Buy	51,500 +30,500	+145%	+$875K	﹤0.01%	2011
2024 Q3	$491K	Sell	21,000 -71,300	-77%	-$1.56M	﹤0.01%	3313
2024 Q2	$1.64M	Buy	92,300 +30,700	+50%	+$490K	﹤0.01%	2301
2024 Q1	$937K	Buy	61,600 +53,800	+690%	+$857K	﹤0.01%	2655
2023 Q4	$133K	Sell	7,800 -21,700	-74%	-$252K	﹤0.01%	3912
2023 Q3	$247K	Buy	29,500 +24,700	+515%	+$344K	﹤0.01%	3393
2023 Q2	$119K	Buy	4,800 +1,100	+30%	+$28.4K	﹤0.01%	3365
2023 Q1	$55.6K	Buy	+3,700	New	+$56.2K	﹤0.01%	3175

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Walleye Capital's TGTX Position: Q1 2026 in Review

Walleye Capital reduced its TG Therapeutics (TGTX) stake by 97% in Q1 2026, selling an estimated $1.74M and leaving 2,018 shares worth $67K. The position accounts for ﹤0.01% of the portfolio, ranked #3813.

Walleye Capital first reported a position in TGTX in Q4 2019 and has held it in 13 quarters since. The position peaked at $1.81M in Q4 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

Walleye Capital held 2,018 shares of TG Therapeutics worth $67K as of Q1 2026.
Walleye Capital sold 58,548 TG Therapeutics shares in Q1 2026, an estimated $1.74M.
TG Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3813 holding.
Walleye Capital first reported a position in TG Therapeutics in Q4 2019 and has held it in 13 quarters since.
Walleye Capital's TG Therapeutics position peaked at $1.81M in Q4 2025.
363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.